Cookies Policy

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

I accept this policy

Find out more here

Cobalamin deficiency and its dynamic impact on neurotoxicity and oxidative stress in Parkinson's patients in on-off status on L-dopa treatment

No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.

Brill’s MyBook program is exclusively available on BrillOnline Books and Journals. Students and scholars affiliated with an institution that has purchased a Brill E-Book on the BrillOnline platform automatically have access to the MyBook option for the title(s) acquired by the Library. Brill MyBook is a print-on-demand paperback copy which is sold at a favorably uniform low price.

This Article is currently unavailable for purchase.
Add to Favorites
You must be logged in to use this functionality

L-Dopa is considered to be one of the best drug therapies in treating Parkinson's patients with positive outcome in the beginning of its treatment. However, as long period of treatment has shown results with both on and off phenomena and high doses show various side effects. In this study, both On and Off PD patients are investigated to determine the role of biochemical markers such as cobalamin (Vitamin B12) and homocysteine in the cerebrospinal fluid (CSF). These biochemical changes in the CSF could be considered as vital information in designing new drugs in treating these patients for a longer period.


Full text loading...


Data & Media loading...

Article metrics loading...



Can't access your account?
  • Key

  • Full access
  • Open Access
  • Partial/No accessInformation